Advertisement

Locostatin Alleviates Liver Fibrosis Induced by Carbon Tetrachloride in Mice

  • Junji MaEmail author
  • Yuzi Qiu
  • Min Wang
  • Ming Zhang
  • Xiaoyi Zhao
  • Huiqing Jiang
Original Article

Abstract

Background and Aims

Liver fibrosis is featured with excessive deposition of extracellular matrix and fibrous connective tissue hyperplasia. The specific inhibitor of Raf-1 kinase inhibitor protein, locostatin, inhibits the migration of hepatic stellate cells. In this study, we investigated the effect of locostatin on liver fibrosis and its underlying mechanism.

Methods

Carbon tetrachloride (CCl4) was used to induce liver fibrosis in mice, and locostatin was injected intraperitoneally. Liver fibrosis was assessed by Masson and Sirius red staining, hydroxyproline (HYP) assay, and collagen percentage area. Collagen I, collagen III, and α-SMA were detected by RT-PCR and western blot. The levels of MMP-13, MMP-2, TIMP-1, and TIMP-2 were estimated by ELISA. Liver inflammation was evaluated by HE staining and immunohistochemistry; liver myeloperoxidase (MPO), superoxide dismutase, and malondialdehyde were measured by ELISA; and cytokines were by Mouse Cytokine Array Q4000.

Results

Compared to the CCl4 group, HYP (208.56 ± 6.12) µg/g, percentage of total collagen at overall region (1.91 ± 0.13), MMP-13/TIMP-1 (0.19 ± 0.01), MPO (1.45 ± 0.04) U/g, TGF-β (2652 ± 91.20), PDGF-AA (3897 ± 290.69), and E-selectin (1569 ± 66.48) in the liver tissues were decreased significantly in the locostatin-treated group.

Conclusions

Locostatin mitigated liver fibrosis and inflammation induced by CCl4. The mechanism is via inhibition inflammatory cytokines, TGF-β, PDGF-AA, and E-selectin.

Keywords

Locostatin Liver fibrosis Collagen Myeloperoxidase E-selectin 

Notes

Acknowledgments

This work was supported by grants to JJM from the National Natural Science Foundation of China (No. 81200311), the National Natural Science Foundation of Hebei Province (China, H2015206431), the scientific research projects funded by talents engineering training in Hebei (China, A2016005065), the Hebei medical research key project (China, 20130184), and the Hebei youth talents project. The authors thank all the members of Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology.

Compliance with ethical standards

Conflict of interest

We declare that we have no conflict of interest on the paper.

References

  1. 1.
    Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669.CrossRefGoogle Scholar
  2. 2.
    Campana L, Iredale JP. Regression of liver fibrosis. Semin Liver Dis. 2017;37:1–10.CrossRefGoogle Scholar
  3. 3.
    Chen L, Guo YZ, Li AD, et al. Knockdown of astrocyte elevated gene-1 inhibits activation of hepatic stellate cells. Dig Dis Sci. 2016;61:1961–1971.  https://doi.org/10.1007/s10620-016-4075-8.CrossRefGoogle Scholar
  4. 4.
    Louka ML, Ramzy MM. Involvement of fibroblast-specific protein 1 (S100A4) and matrix metalloproteinase-13 (MMP-13) in CCl4-induced reversible liver fibrosis. Gene. 2016;579:29–33.CrossRefGoogle Scholar
  5. 5.
    Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol. 2010;53:132–144.CrossRefGoogle Scholar
  6. 6.
    Ma J, Li F, Liu L, et al. Raf kinase inhibitor protein inhibits cell proliferation but promotes cell migration in rat hepatic stellate cells. Liver Int. 2009;29:567–574.CrossRefGoogle Scholar
  7. 7.
    Huang Q, Bai F, Nie J, et al. Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression. Int Immunopharmacol. 2017;42:130–138.CrossRefGoogle Scholar
  8. 8.
    Huang Q, Liang C, Wei L, et al. Raf kinase inhibitory protein down-expression exacerbates hepatic fibrosis in vivo and in vitro. Cell Physiol Biochem. 2016;40:49–61.CrossRefGoogle Scholar
  9. 9.
    Lin X, Bai F, Nie J, et al. Didymin alleviates hepatic fibrosis through inhibiting ERK and PI3 K/Akt pathways via regulation of raf kinase inhibitor protein. Cell Physiol Biochem. 2016;40:1422–1432.CrossRefGoogle Scholar
  10. 10.
    Janjusevic M, Greco S, Islam MS, et al. Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells. Fertil Steril. 2016;106:1530–1538.CrossRefGoogle Scholar
  11. 11.
    Crassini K, Pyke T, Shen Y, et al. Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leuk Lymphoma. 2018;59:2917–2928.CrossRefGoogle Scholar
  12. 12.
    Magdaleno F, Arriazu E, Ruiz de Galarreta M, et al. Cartilage oligomeric matrix protein participates in the pathogenesis of liver fibrosis. J Hepatol. 2016;65:963–971.CrossRefGoogle Scholar
  13. 13.
    Tan Z, Qian X, Jiang R, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 2013;191:1835–1844.CrossRefGoogle Scholar
  14. 14.
    Liu F, Chen L, Rao HY, et al. Automated evaluation of liver fibrosis in thioacetamide, carbon tetrachloride, and bile duct ligation rodent models using second-harmonic generation/two-photon excited fluorescence microscopy. Lab Investig. 2017;97:84–92.CrossRefGoogle Scholar
  15. 15.
    Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438–1450.CrossRefGoogle Scholar
  16. 16.
    Shi D, Zhang J, Zhou Q, et al. Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs. Gut. 2017;66:955–964.CrossRefGoogle Scholar
  17. 17.
    Ménoret A, McAleer JP, Ngoi SM, et al. The oxazolidinone derivative locostatin induces cytokine appeasement. J Immunol. 2009;183:7489–7496.CrossRefGoogle Scholar
  18. 18.
    Scheving LA, Zhang X, Threadgill DW, Russell WE. Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2016;311:G807–G816.CrossRefGoogle Scholar
  19. 19.
    Jiménez Calvente C, Sehgal A, Popov Y, et al. Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology. 2015;62:1285–1297.CrossRefGoogle Scholar
  20. 20.
    Karsdal MA, Henriksen K, Nielsen MJ, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol. 2016;311:G1009–G1017.CrossRefGoogle Scholar
  21. 21.
    Watanabe T, Niioka M, Hozawa S, et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol. 2000;33:224–235.CrossRefGoogle Scholar
  22. 22.
    Li X, Wang L, Chen C. Effects of exogenous thymosin β4 on carbon tetrachloride-induced liver injury and fibrosis. Sci Rep. 2017;7:5872.  https://doi.org/10.1038/s41598-017-06318-5.CrossRefGoogle Scholar
  23. 23.
    Wu MH, Chen YL, Lee KH, et al. Glycosylation-dependent galectin-1/neuropilin-1 interactions promote liver fibrosis through activation of TGF-β- and PDGF-like signals in hepatic stellate cells. Sci Rep. 2017;7:11006.  https://doi.org/10.1038/s41598-017-11212-1.CrossRefGoogle Scholar
  24. 24.
    Liu T, Xu L, Wang C, et al. Shikonin alleviates hepatic fibrosis and autophagy via inhibition of TGF-β1/Smads pathway. J Gastroenterol Hepatol. 2018;.  https://doi.org/10.1111/jgh.14299.Google Scholar
  25. 25.
    Gong J, Tu W, Han J, et al. Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx. Sci Rep. 2016;6:37717.  https://doi.org/10.1038/srep37717.CrossRefGoogle Scholar
  26. 26.
    Breitkopf K, Roeyen CV, Sawitza I, Wickert L, Floege J, Gressner AM. Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine. 2005;31:349–357.CrossRefGoogle Scholar
  27. 27.
    Thieringer F, Maass T, Czochra P, et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene. 2008;423:23–28.CrossRefGoogle Scholar
  28. 28.
    Robert S, Gicquel T, Bodin A, Lagente V, Boichot E. Characterization of the MMP/TIMP imbalance and collagen production induced by IL-1β or TNF-α release from human hepatic stellate cells. PLoS ONE. 2016;11:e0153118.  https://doi.org/10.1371/journal.pone.0153118.CrossRefGoogle Scholar
  29. 29.
    Du K, Hyun J, Premont RT, et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. 2018;154:1465–1479.CrossRefGoogle Scholar
  30. 30.
    Bertola A, Park O, Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology. 2013;58:1814–1823.CrossRefGoogle Scholar
  31. 31.
    Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 2018;.  https://doi.org/10.1002/hep.29802.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Junji Ma
    • 1
    Email author
  • Yuzi Qiu
    • 1
  • Min Wang
    • 1
  • Ming Zhang
    • 1
  • Xiaoyi Zhao
    • 1
  • Huiqing Jiang
    • 1
  1. 1.Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of GastroenterologyHebei Institute of GastroenterologyShijiazhuangChina

Personalised recommendations